NIH researchers prevent blindness in animal models of dry AMD

Findings set stage for first clinical trial of stem cell-based therapeutic approach for AMD. Using a novel patient-specific stem cell-based therapy, researchers at the National Eye Institute (NEI) prevented blindness in animal models of geographic atrophy, the advanced “dry” form of age-related macular degeneration (AMD). The protocols established by the animal study* set the stage [Read More]

KSI-301 Joins List of Proposed Longer Lasting Anti-VEGF Drugs

Kodiak Sciences Inc. has announced promising results from their Phase 1 clinical trial of KSI-301, a novel anti-VEGF compound for the treatment of age-related macular degeneration, retinal vein occlusion, and diabetic macular edema. Currently approved anti-VEGF drugs require several monthly “loading dosages” at the beginning of the treatment regimen. Twelve weeks after a single dose [Read More]

Iron Supplementation Associated With Wet AMD

A report published in Review of Optometry on November 5, 2018 announced research* showing that non-anemic patients with wet age-related macular degeneration (wAMD) who take oral iron supplements may be at risk of retinal/subretinal hemorrhage. Researchers have found that use of oral iron supplements was significantly associated with retinal/subretinal hemorrhage at baseline in patients with [Read More]